Scoop has an Ethical Paywall
Work smarter with a Pro licence Learn More

Video | Business Headlines | Internet | Science | Scientific Ethics | Technology | Search

 

Living Cell Technologies saluted by bioscience peers


Living Cell Technologies saluted by bioscience peers

Auckland New Zealand March 20: Living Cell Technologies (LCT) has been named as the New Zealand’s top bioscience company and Dr Doug Wilson as the Janssen Distinguished Biotechnologist at the 2013 NZBIO Conference Awards.


Dr Andrea Grant of LCT

Dr George Slim, CEO of NZBIO, says the judges rewarded LCT for taking a complex, world-first treatment technology over some very tough regulatory hurdles to show considerable promise in human trials.

“The company has a strong portfolio of follow on products and has recently entered into a partnership deal with a major international pharmaceutical company,” the judges said.

Dr Slim said it had been tough selecting the top bioscience company, because among the finalists there was a range of excellent businesses, all of which had different business models.

The top biotechnologist, Dr Doug Wilson, is a graduate from the University of Auckland medical school. He did post graduate research in London before starting an academic career in Auckland. In 1987 he changed tack and became NZ medical director of Boehringer Ingelheim in New Zealand.


Dr Doug Wilson

Advertisement - scroll to continue reading

Are you getting our free newsletter?

Subscribe to Scoop’s 'The Catch Up' our free weekly newsletter sent to your inbox every Monday with stories from across our network.

Dr Wilson rose to become the head of Boehringer Ingelheim Clinical Research Institute, overseeing all clinical research worldwide for the company. He then became head of medicine and regulatory affairs worldwide, based in Germany, overseeing all the research programmes for the company and all interactions with the European Medicines Evaluation Agency (EMEA).

NZBIO also salutes emerging talent in the bioscience sector. The emerging company of the year must be less than five-years-old and have a product pipeline and a development strategy, among other criteria. The young biotechnologist of the year is awarded to someone under 40-years-old whose work demonstrates the potential for future leadership in New Zealand’s bioeconomy.

The emerging company of the year was awarded to Biotelliga. The judges commented that Biotelliga shows strong links between its science, the industry sector and consumers’ needs in an important area of the New Zealand economy.

Biotelliga, which is based at Pukekohe near Auckland, develops and produces biological, sustainable, non-chemical based crop spray solutions for the effective management and control of pests and diseases in agriculture and horticulture.

The young biotechnologist for 2013 was awarded to Hywel Griffiths from Photonz, an Auckland-based company which produces the omega-3 fatty acid eicosapentaenoic acid (EPA) from its primary source, marine microalgae. EPA is a critical ingredient in regulated pharmaceutical products and medicinal foods addressing cardiovascular disease.

The judges commented that Dr Griffiths has gone from an outstanding record of doctoral and postdoctoral research in Europe to making a significant contribution to scale up and development of bioprocesses for a leading New Zealand company.

“Dr Griffiths is an acknowledged world leader in a complex area of science and has recruited and led an excellent team of scientists as the company grows rapidly,” the judges said.

Dr Slim says while there is plenty of young talent about and the emerging companies who were finalists were good companies, NZBIO is concerned that the pipeline of emerging bioscience companies is less than what it has been in the past 10 years.

NZBIO has been reviewing its past decade and says while the sector has got close to some goals outlined for it in 2003, like the rest of the world there has been a levelling out in the growth of the sector while governments realign their strategies and concentrate on “outputs”, often at the expense of supporting innovation and entrepreneurial ideas with world class potential.

“New Zealand’s innovation is celebrated internationally and its entrepreneurs have attracted foreign investment,” Dr Slim says. “With the limited pool of capital beyond the first couple of stages of development in New Zealand, it is vital for our companies to retain NZ support if they are to realise the potential of their technologies internationally.”

Ends

© Scoop Media

Advertisement - scroll to continue reading
 
 
 
Business Headlines | Sci-Tech Headlines

 
GenPro: General Practices Begin Issuing Clause 14 Notices

GenPro has been copied into a rising number of Clause 14 notices issued since the NZNO lodged its Primary Practice Pay Equity Claim against General Practice employers in December 2023.More

SPADA: Screen Industry Unites For Streaming Platform Regulation & Intellectual Property Protections

In an unprecedented international collaboration, representatives of screen producing organisations from around the world have released a joint statement.More

 
 
 
 
 
 
 
 
 
 
 
 

Join Our Free Newsletter

Subscribe to Scoop’s 'The Catch Up' our free weekly newsletter sent to your inbox every Monday with stories from across our network.